We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 355

Biotech Life Sciences trade mission to Australia announced
  • Shook Hardy & Bacon LLP
  • Australia, USA
  • June 21 2012

The U.S. Department of Commerce, International Trade Administration and U.S. and Foreign Commercial Service have announced an October 29-November 2, 2012, Biotech Life Sciences trade mission to Australia


Igenica closes $33 million in Series C financing for cancer therapeutics
  • Shook Hardy & Bacon LLP
  • USA
  • June 21 2012

Igenica Inc., a biopharmaceutical company seeking to discover and develop antibodies for cancer treatment, has reportedly raised $33 million in Series C funding


Federal Courts of Appeals conflict over validity of pay-for-delay deals
  • Shook Hardy & Bacon LLP
  • USA
  • August 2 2012

The Third Circuit Court of Appeals issued a ruling in mid-July that found “any payment from a patent holder to a generic patent challenger who agrees to delay entry into the market must be treated by a factfinder as prima facie evidence of an unreasonable restraint of trade,” thus supporting the Federal Trade Commission’s (FTC’s) view that pay-for-delay deals that settle patent disputes between name-brand pharmaceutical companies and their generic drug competitors violate antitrust law


Supplemental briefs filed in stem cell funding dispute
  • Shook Hardy & Bacon LLP
  • USA
  • July 14 2011

The parties to a dispute over whether National Institutes of Health (NIH) guidelines on stem cell research violate a congressional appropriations rider that bars federal funding for research in which a human embryo is destroyed have filed their supplemental briefs on competing motions for summary judgment pending before a U.S. district court in Washington, D.C


U.S. Senators propose subjecting compounded drugs to federal regulation
  • Shook Hardy & Bacon LLP
  • USA
  • May 2 2013

Bipartisan Senate health committee leaders have released draft legislation that would give the Food and Drug Administration (FDA) greater oversight


FDA targets “high-risk” compounding pharmacies for inspection
  • Shook Hardy & Bacon LLP
  • USA
  • March 7 2013

The Food and Drug Administration (FDA) has reportedly begun focusing its investigative efforts on compounding pharmacies at "high risk" for


Congress advances pharma supply chain and animal-drug user-fee laws
  • Shook Hardy & Bacon LLP
  • USA
  • May 16 2013

The House Energy and Commerce Subcommittee on Health has reportedly approved draft legislation that would change the existing lot-level


News Bytes - May 16, 2013
  • Shook Hardy & Bacon LLP
  • USA
  • May 16 2013

The National Institutes of Health (NIH) Office of Biotechnology Activities proposes revising the "NIH Guidelines for Research Involving Recombinant


Universities abroad experiment with no-fee licensing to drive biotech partnerships
  • Shook Hardy & Bacon LLP
  • European Union, United Kingdom, USA, Australia, Canada
  • May 16 2013

Universities in Australia, Canada, Europe, and the United Kingdom have reportedly embraced a 2010 Glasgow University initiative under which companies


NASDAQ Biotechnology Index surpasses all-time high in 1Q13
  • Shook Hardy & Bacon LLP
  • USA
  • May 16 2013

The NASDAQ Biotechnology Index reportedly rose in the first quarter of 2013 (1Q13) above levels last seen during the 2000 genomics bubble peakthe